Qiagen N.V.(QGEN)Earnings, Financials & Key Ratios
QGEN•NYSE
$34.46
$7.1B mkt cap·16.9× P/E·Price updated May 6, 2026
AboutQIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.Show more
- Revenue$2.09B+5.7%
- EBITDA$714M+137.2%
- Net Income$425M+408.3%
- EPS (Diluted)2.04+436.8%
- Gross Margin61.79%+26.4%
- EBITDA Margin34.17%+124.6%
- Operating Margin24.9%+404.0%
- Net Margin20.33%+381.1%
- ROE11.57%+410.3%
- ROIC8.57%+446.3%
- Debt/Equity0.44-2.9%
- Interest Coverage15.74+318.3%
QGEN Key Insights
Qiagen N.V. (QGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 21.7% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 4.8% through buybacks
- ✓Healthy 5Y average net margin of 16.9%
✗Weaknesses
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
QGEN Price & Volume
Qiagen N.V. (QGEN) stock price & volume — 10-year historical chart
Loading chart...
QGEN Growth Metrics
Qiagen N.V. (QGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.02%
5 Years2.25%
3 Years-0.81%
TTM5.65%
Profit CAGR
10 Years12.56%
5 Years3.42%
3 Years0.13%
TTM408.28%
EPS CAGR
10 Years13.8%
5 Years44.84%
3 Years-0.16%
TTM418.42%
Return on Capital
10 Years6.19%
5 Years8.55%
3 Years6.45%
Last Year9.52%
QGEN Recent Earnings
Qiagen N.V. (QGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 12/12 qtrs (100%)
Q1 2026Latest
Feb 4, 2026EPS
$0.62
Est $0.61
+1.6%
Revenue
$540M
Est $528M
+2.3%
Q4 2025
Nov 4, 2025EPS
$0.64
Est $0.61
+4.9%
Revenue
$533M
Est $526M
+1.3%
Q3 2025
Aug 5, 2025EPS
$0.60
Est $0.60
+0.0%
Revenue
$534M
Est $516M
+3.4%
Q2 2025
May 7, 2025EPS
$0.55
Est $0.50
+9.3%
Revenue
$483M
Est $469M
+3.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 4, 2026 | $0.62vs $0.61+1.6% | $540Mvs $528M+2.3% |
| Q4 2025 | Nov 4, 2025 | $0.64vs $0.61+4.9% | $533Mvs $526M+1.3% |
| Q3 2025 | Aug 5, 2025 | $0.60vs $0.60+0.0% | $534Mvs $516M+3.4% |
| Q2 2025 | May 7, 2025 | $0.55vs $0.50+9.3% | $483Mvs $469M+3.1% |
Based on last 12 quarters of dataView full earnings history →
QGEN Peer Comparison
Qiagen N.V. (QGEN) competitors in Lab Consumables and Sample Preparation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 123.8B | 174.92 | 34.71 | 2.9% | 14.89% | 7.06% | 0.35 | |
 BIO | 6.99B | 259.02 | 9.29 | 0.65% | 6.52% | 2.4% | 0.21 | |
 TECH | 7.42B | 47.41 | 103.05 | 5.23% | 9.05% | 5.48% | 0.23 |
Compare QGEN vs Peers
Qiagen N.V. (QGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QGEN Income Statement
Qiagen N.V. (QGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.42B | 1.5B | 1.53B | 1.87B | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Revenue Growth % | 5.95% | 5.95% | 1.64% | 22.53% | 20.39% | -4.89% | -8.23% | 0.66% | 5.65% |
| Cost of Goods Sold | 494.98M | 500.89M | 521.16M | 637.63M | 800.84M | 756.96M | 731.62M | 1.01B | 798.5M |
| COGS % of Revenue | 34.92% | 33.35% | 34.14% | 34.09% | 35.57% | 35.35% | 37.23% | 51.1% | 38.21% |
| Gross Profit | 922.56M▲ 0% | 1B▲ 8.5% | 1.01B▲ 0.4% | 1.23B▲ 22.6% | 1.45B▲ 17.7% | 1.38B▼ 4.6% | 1.23B▼ 10.9% | 967.35M▼ 21.6% | 1.29B▲ 33.5% |
| Gross Margin % | 65.08% | 66.65% | 65.86% | 65.91% | 64.43% | 64.65% | 62.77% | 48.9% | 61.79% |
| Gross Profit Growth % | 9.22% | 8.5% | 0.43% | 22.63% | 17.69% | -4.57% | -10.9% | -21.59% | 33.51% |
| Operating Expenses | 769.14M | 734.38M | 1.03B | 846.28M | 820.74M | 853.1M | 823.75M | 869.64M | 771.18M |
| OpEx % of Revenue | 54.26% | 48.9% | 67.57% | 45.25% | 36.45% | 39.84% | 41.91% | 43.96% | 36.9% |
| Selling, General & Admin | 575.66M | 533.5M | 504.17M | 525.36M | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| SG&A % of Revenue | 40.61% | 35.52% | 33.03% | 28.09% | 25.96% | 28.2% | 29.47% | 28.53% | 27.93% |
| Research & Development | 154.08M | 161.85M | 157.45M | 149.07M | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| R&D % of Revenue | 10.87% | 10.78% | 10.31% | 7.97% | 8.44% | 8.87% | 10.1% | 9.78% | 8.97% |
| Other Operating Expenses | 137.42M | 75.68M | 369.78M | 171.85M | 46.3M | 59.3M | 46.07M | 111.78M | 0 |
| Operating Income | 153.42M▲ 0% | 266.58M▲ 73.8% | -26.14M▼ 109.8% | 386.43M▲ 1578.5% | 630.08M▲ 63.1% | 531.46M▼ 15.7% | 409.94M▼ 22.9% | 97.71M▼ 76.2% | 520.31M▲ 432.5% |
| Operating Margin % | 10.82% | 17.75% | -1.71% | 20.66% | 27.98% | 24.82% | 20.86% | 4.94% | 24.9% |
| Operating Income Growth % | 55.24% | 73.76% | -109.8% | 1578.54% | 63.05% | -15.65% | -22.87% | -76.16% | 432.5% |
| EBITDA | 369.87M | 473.02M | 205.32M | 591.45M | 845.01M | 739.86M | 615.27M | 300.98M | 714.06M |
| EBITDA Margin % | 26.09% | 31.5% | 13.45% | 31.62% | 37.53% | 34.55% | 31.31% | 15.21% | 34.17% |
| EBITDA Growth % | 18.59% | 27.89% | -56.59% | 188.06% | 42.87% | -12.44% | -16.84% | -51.08% | 137.24% |
| D&A (Non-Cash Add-back) | 216.45M | 206.44M | 231.46M | 205.01M | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| EBIT | 164.06M | 293.03M | -3.59M | 510.79M | 680.31M | 570.96M | 483.22M | 164.99M | 523.52M |
| Net Interest Income | -39.04M | -46.44M | -52.07M | -61.28M | -44.92M | -25.6M | 25.58M | 24.18M | 31.06M |
| Interest Income | 10.64M | 20.85M | 22.11M | 10.03M | 9.55M | 32.76M | 78.99M | 68.02M | 64.32M |
| Interest Expense | 49.69M | 67.29M | 74.19M | 71.32M | 54.48M | 58.36M | 53.41M | 43.84M | 33.26M |
| Other Income/Expense | -39.04M | -40.84M | -51.64M | 53.04M | -4.25M | -18.86M | 19.87M | 23.44M | -30.04M |
| Pretax Income | 114.38M▲ 0% | 225.74M▲ 97.4% | -77.78M▼ 134.5% | 439.47M▲ 665.0% | 625.83M▲ 42.4% | 512.6M▼ 18.1% | 429.81M▼ 16.2% | 121.15M▼ 71.8% | 490.26M▲ 304.7% |
| Pretax Margin % | 8.07% | 15.03% | -5.1% | 23.5% | 27.79% | 23.94% | 21.87% | 6.12% | 23.46% |
| Income Tax | 73.98M | 35.36M | -36.32M | 80.28M | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Effective Tax Rate % | 64.68% | 15.66% | 46.7% | 18.27% | 18.09% | 17.44% | 20.59% | 31% | 13.34% |
| Net Income | 40.39M▲ 0% | 190.38M▲ 371.3% | -41.45M▼ 121.8% | 359.19M▲ 966.5% | 512.6M▲ 42.7% | 423.21M▼ 17.4% | 341.3M▼ 19.4% | 83.59M▼ 75.5% | 424.88M▲ 408.3% |
| Net Margin % | 2.85% | 12.68% | -2.72% | 19.2% | 22.77% | 19.76% | 17.37% | 4.23% | 20.33% |
| Net Income Growth % | -49.76% | 371.31% | -121.77% | 966.45% | 42.71% | -17.44% | -19.35% | -75.51% | 408.28% |
| Net Income (Continuing) | 40.39M | 190.38M | -41.45M | 359.19M | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.17▲ 0% | 0.82▲ 382.4% | -0.19▼ 123.2% | 0.32▲ 268.4% | 2.47▲ 671.9% | 2.05▼ 17.0% | 1.65▼ 19.5% | 0.38▼ 77.0% | 2.04▲ 436.8% |
| EPS Growth % | -51.43% | 382.35% | -123.17% | 268.42% | 671.88% | -17% | -19.51% | -76.97% | 436.84% |
| EPS (Basic) | 0.18 | 0.84 | -0.19 | 0.33 | 2.52 | 2.08 | 1.67 | 0.39 | 2.04 |
| Diluted Shares Outstanding | 233.01M | 233.46M | 219.97M | 227.19M | 225.07M | 223.23M | 217.49M | 218.47M | 207.94M |
| Basic Shares Outstanding | 228.07M | 225.51M | 219.97M | 221.57M | 221.14M | 220.75M | 217.49M | 216.44M | 207.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | 12.77% |
QGEN Balance Sheet
Qiagen N.V. (QGEN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.65B | 2.16B | 1.57B | 1.62B | 2.11B | 2.39B | 2.15B | 1.96B | 2B |
| Cash & Short-Term Investments | 1.04B | 1.42B | 753.23M | 715.23M | 1.07B | 1.42B | 1.06B | 1.15B | 1.1B |
| Cash Only | 679.62M | 1.18B | 623.65M | 597.98M | 880.52M | 730.67M | 668.08M | 663.55M | 839M |
| Short-Term Investments | 359.2M | 234.61M | 129.59M | 117.25M | 184.78M | 687.6M | 389.7M | 489.44M | 259.91M |
| Accounts Receivable | 386.1M | 397.68M | 484.61M | 486.61M | 469.66M | 434.07M | 515.64M | 458.98M | 402.61M |
| Days Sales Outstanding | 99.42 | 96.65 | 115.88 | 94.96 | 76.13 | 73.98 | 95.77 | 84.69 | 70.31 |
| Inventory | 155.93M | 162.91M | 170.7M | 291.18M | 327.52M | 357.96M | 398.38M | 279.26M | 301.89M |
| Days Inventory Outstanding | 114.98 | 118.71 | 119.55 | 166.68 | 149.28 | 172.61 | 198.75 | 100.83 | 137.99 |
| Other Current Assets | 7.48M | 102.75M | 116.29M | 70.23M | 186.48M | 132.7M | 130.9M | 26.85M | 191.66M |
| Total Non-Current Assets | 3.39B | 3.59B | 3.67B | 4.25B | 4.04B | 3.89B | 3.97B | 3.73B | 4.3B |
| Property, Plant & Equipment | 494.32M | 511.66M | 455.24M | 559.37M | 638.18M | 662.17M | 765.04M | 753.61M | 923.95M |
| Fixed Asset Turnover | 2.87x | 2.94x | 3.35x | 3.34x | 3.53x | 3.23x | 2.57x | 2.62x | 2.26x |
| Goodwill | 2.01B | 2.11B | 2.14B | 2.36B | 2.35B | 2.35B | 2.48B | 2.43B | 2.7B |
| Intangible Assets | 499.32M | 475.04M | 632.43M | 726.19M | 627.44M | 544.8M | 526.82M | 303.81M | 386.43M |
| Long-Term Investments | 276.46M | 369.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 68.18M | 85.45M | 380.65M | 540.74M | 348.07M | 334.25M | 200.04M | 246.93M | 289.85M |
| Total Assets | 5.04B▲ 0% | 5.75B▲ 14.1% | 5.24B▼ 8.9% | 5.87B▲ 12.1% | 6.15B▲ 4.7% | 6.29B▲ 2.3% | 6.12B▼ 2.7% | 5.69B▼ 7.0% | 6.3B▲ 10.7% |
| Asset Turnover | 0.28x | 0.26x | 0.29x | 0.32x | 0.37x | 0.34x | 0.32x | 0.35x | 0.33x |
| Asset Growth % | 16.95% | 14.09% | -8.92% | 12.11% | 4.72% | 2.29% | -2.74% | -6.96% | 10.66% |
| Total Current Liabilities | 324.79M | 972.19M | 951.35M | 572.17M | 1.52B | 974.52M | 1.08B | 543.63M | 512.14M |
| Accounts Payable | 59.2M | 69.42M | 84.77M | 118.15M | 101.22M | 98.73M | 84.16M | 83.27M | 72.66M |
| Days Payables Outstanding | 43.66 | 50.58 | 59.37 | 67.63 | 46.14 | 47.61 | 41.98 | 30.07 | 33.21 |
| Short-Term Debt | 10.39M | 503.18M | 285.24M | 42.54M | 847.63M | 389.55M | 587.97M | 53.48M | 0 |
| Deferred Revenue (Current) | 49.36M | 45.36M | 48.52M | 57.07M | 63.37M | 69M | 66.43M | 70.83M | 0 |
| Other Current Liabilities | 120.84M | 257.32M | 158.82M | 119.31M | 257.65M | 192.19M | 118.03M | 113.21M | 439.48M |
| Current Ratio | 5.07x | 2.22x | 1.65x | 2.84x | 1.39x | 2.46x | 1.99x | 3.61x | 3.90x |
| Quick Ratio | 4.59x | 2.05x | 1.47x | 2.33x | 1.17x | 2.09x | 1.62x | 3.09x | 3.31x |
| Cash Conversion Cycle | 170.74 | 164.78 | 176.07 | 194.01 | 179.28 | 198.98 | 252.53 | 155.45 | 175.09 |
| Total Non-Current Liabilities | 2.17B | 2.14B | 1.75B | 2.5B | 1.53B | 1.85B | 1.23B | 1.58B | 2.01B |
| Long-Term Debt | 1.76B | 1.67B | 1.42B | 1.88B | 1.17B | 1.54B | 1B | 1.43B | 1.65B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 76.53M | 71.41M | 79.06M | 96.66M | 0 |
| Deferred Tax Liabilities | 76.73M | 63.41M | 23.44M | 39.22M | 37.59M | 17.5M | 12.8M | 22.7M | 0 |
| Other Non-Current Liabilities | 337.74M | 406.67M | 303.13M | 580.18M | 236.83M | 199.19M | 119.68M | 6.57M | 351.24M |
| Total Liabilities | 2.5B | 3.11B | 2.7B | 3.07B | 3.05B | 2.82B | 2.31B | 2.12B | 2.52B |
| Total Debt | 1.77B | 2.17B | 1.73B | 1.95B | 2.12B | 2.03B | 1.69B | 1.61B | 1.65B |
| Net Debt | 1.09B | 989.82M | 1.1B | 1.35B | 1.24B | 1.3B | 1.02B | 945.64M | 815.42M |
| Debt / Equity | 0.70x | 0.83x | 0.68x | 0.70x | 0.68x | 0.58x | 0.44x | 0.45x | 0.44x |
| Debt / EBITDA | 4.78x | 4.60x | 8.40x | 3.29x | 2.51x | 2.74x | 2.75x | 5.35x | 2.32x |
| Net Debt / EBITDA | 2.94x | 2.09x | 5.36x | 2.28x | 1.46x | 1.75x | 1.66x | 3.14x | 1.14x |
| Interest Coverage | 3.30x | 4.35x | -0.05x | 7.16x | 12.49x | 9.78x | 9.05x | 3.76x | 15.74x |
| Total Equity | 2.54B▲ 0% | 2.63B▲ 3.7% | 2.54B▼ 3.7% | 2.8B▲ 10.3% | 3.1B▲ 10.7% | 3.47B▲ 12.0% | 3.81B▲ 9.8% | 3.57B▼ 6.3% | 3.78B▲ 5.9% |
| Equity Growth % | -2.54% | 3.7% | -3.73% | 10.3% | 10.68% | 11.95% | 9.84% | -6.31% | 5.91% |
| Book Value per Share | 10.91 | 11.29 | 11.53 | 12.32 | 13.76 | 15.53 | 17.51 | 16.33 | 18.17 |
| Total Shareholders' Equity | 2.54B | 2.63B | 2.54B | 2.8B | 3.1B | 3.47B | 3.81B | 3.57B | 3.78B |
| Common Stock | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.6M | 2.53M |
| Retained Earnings | 1.25B | 1.38B | 1.18B | 1.32B | 1.79B | 2.16B | 2.46B | 2.45B | 2.75B |
| Treasury Stock | -118.99M | -178.9M | -111.97M | -118.3M | -189.73M | -160.19M | -133.02M | -74.92M | -31.82M |
| Accumulated OCI | -220.76M | -310.64M | -309.62M | -243.82M | -326.67M | -404.09M | -433.83M | -474.54M | -377.31M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QGEN Cash Flow Statement
Qiagen N.V. (QGEN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 286.78M | 359.5M | 330.84M | 492.27M | 639M | 715.26M | 459.45M | 673.55M | 654.33M |
| Operating CF Margin % | 20.23% | 23.94% | 21.67% | 26.32% | 28.38% | 33.4% | 23.38% | 34.05% | 31.31% |
| Operating CF Growth % | -16.05% | 25.36% | -7.97% | 48.79% | 29.81% | 11.93% | -35.76% | 46.6% | -2.85% |
| Net Income | 40.39M | 190.38M | -41.45M | 73.64M | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Depreciation & Amortization | 216.45M | 206.44M | 231.46M | 209.97M | 214.93M | 208.4M | 205.34M | 203.27M | 197.11M |
| Stock-Based Compensation | 34.44M | 40.11M | 65.89M | 40.94M | 38.39M | 49.51M | 47.1M | 43.63M | 50.4M |
| Deferred Taxes | 39.55M | -23.27M | -55.36M | -14.26M | -5.29M | -9.6M | 10.73M | -23.04M | -20.07M |
| Other Non-Cash Items | 23.18M | 41M | 174.63M | 165.18M | 8.38M | 75.63M | 41.94M | 230.65M | 36.51M |
| Working Capital Changes | -67.23M | -95.16M | -44.32M | 16.8M | -130.01M | -31.88M | -186.96M | 135.45M | -34.51M |
| Change in Receivables | -34.16M | -41.81M | -39.58M | -14.71M | -7.4M | 15.45M | -55.12M | 12.22M | 0 |
| Change in Inventory | -21.63M | -36.92M | -30.03M | -107.57M | -81.8M | -61.95M | -44.79M | 87.75M | 0 |
| Change in Payables | 4.32M | 6.99M | 9.25M | 8.44M | -5.97M | -1.76M | -22.42M | 1.45M | 0 |
| Cash from Investing | -464.26M | -211.36M | -222.28M | -453.29M | -202.43M | -726.76M | -87.66M | -249.23M | -305.28M |
| Capital Expenditures | -124.41M | -150.76M | -274.88M | -304.24M | -206.53M | -149.34M | -162.8M | -167.17M | -207.13M |
| CapEx % of Revenue | 8.78% | 10.04% | 18.01% | 16.27% | 9.17% | 6.97% | 8.28% | 8.45% | 9.91% |
| Acquisitions | -50.55M | -172.83M | -67.06M | -239.57M | -16.63M | -63.65M | -149.53M | 0 | -291.23M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -22.98M | -2.13M | 22.7M | -66.57M | 61.47M | -9.77M | -66.55M | 21.35M | -32.16M |
| Cash from Financing | 387.19M | 360.41M | -639.08M | -74.32M | -150.37M | -125.8M | -433.83M | -422.9M | -178.98M |
| Debt Issued (Net) | 722.86M | 493.57M | -505.43M | -35.55M | -41.34M | -108.55M | -436.76M | -107.33M | 208.15M |
| Equity Issued (Net) | -304.92M | -104.69M | -72.38M | -77.84M | -92.07M | -25.36M | -17.68M | -292.1M | -307.36M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -54.24M |
| Share Repurchases | -60.97M | -104.69M | -74.45M | -63.99M | -99.99M | -25.36M | -17.68M | -292.1M | -307.36M |
| Other Financing | -30.76M | -28.48M | -61.28M | 39.07M | -16.95M | 8.11M | 20.61M | -23.47M | -25.53M |
| Net Change in Cash | 218.53M▲ 0% | 501.37M▲ 129.4% | -529.69M▼ 205.6% | -31.23M▲ 94.1% | 282.53M▲ 1004.8% | -149.85M▼ 153.0% | -62.59M▲ 58.2% | -4.53M▲ 92.8% | 175.45M▲ 3973.9% |
| Free Cash Flow | 162.37M▲ 0% | 208.73M▲ 28.6% | 55.96M▼ 73.2% | 188.03M▲ 236.0% | 432.47M▲ 130.0% | 565.93M▲ 30.9% | 296.65M▼ 47.6% | 506.38M▲ 70.7% | 453.28M▼ 10.5% |
| FCF Margin % | 11.45% | 13.9% | 3.67% | 10.05% | 19.21% | 26.43% | 15.09% | 25.6% | 21.69% |
| FCF Growth % | -34.44% | 28.55% | -73.19% | 236.02% | 129.99% | 30.86% | -47.58% | 70.7% | -10.49% |
| FCF per Share | 0.70 | 0.89 | 0.25 | 0.83 | 1.92 | 2.54 | 1.36 | 2.32 | 2.18 |
| FCF Conversion (FCF/Net Income) | 7.10x | 1.89x | -7.98x | 1.37x | 1.25x | 1.69x | 1.35x | 8.06x | 1.54x |
| Interest Paid | 20.25M | 25.9M | 29.72M | 25.35M | 21.59M | 23.21M | 20.35M | 24.18M | 0 |
| Taxes Paid | 40.5M | 29.32M | 41.47M | 42.57M | 102.08M | 120.48M | 82.41M | 15.68M | 0 |
QGEN Key Ratios
Qiagen N.V. (QGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 3.11% | 1.57% | 7.36% | -1.6% | 13.47% | 17.39% | 12.9% | 9.38% | 2.27% | 11.57% |
| Return on Invested Capital (ROIC) | 2.25% | 3.35% | 5.51% | -0.54% | 7.45% | 11.15% | 8.76% | 6.41% | 1.57% | 8.57% |
| Gross Margin | 63.13% | 65.08% | 66.65% | 65.86% | 65.91% | 64.43% | 64.65% | 62.77% | 48.9% | 61.79% |
| Net Margin | 6.01% | 2.85% | 12.68% | -2.72% | 19.2% | 22.77% | 19.76% | 17.37% | 4.23% | 20.33% |
| Debt / Equity | 0.41x | 0.70x | 0.83x | 0.68x | 0.70x | 0.68x | 0.58x | 0.44x | 0.45x | 0.44x |
| Interest Coverage | 2.46x | 3.30x | 4.35x | -0.05x | 7.16x | 12.49x | 9.78x | 9.05x | 3.76x | 15.74x |
| FCF Conversion | 4.25x | 7.10x | 1.89x | -7.98x | 1.37x | 1.25x | 1.69x | 1.35x | 8.06x | 1.54x |
| Revenue Growth | 4.45% | 5.95% | 5.95% | 1.64% | 22.53% | 20.39% | -4.89% | -8.23% | 0.66% | 5.65% |
QGEN Frequently Asked Questions
Qiagen N.V. (QGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Qiagen N.V. (QGEN) reported $2.09B in revenue for fiscal year 2025. This represents a 3756% increase from $54.2M in 1996.
Qiagen N.V. (QGEN) grew revenue by 5.7% over the past year. This is steady growth.
Yes, Qiagen N.V. (QGEN) is profitable, generating $424.9M in net income for fiscal year 2025 (20.3% net margin).
Dividend & Returns
Yes, Qiagen N.V. (QGEN) pays a dividend with a yield of 0.76%. This makes it attractive for income-focused investors.
Qiagen N.V. (QGEN) has a return on equity (ROE) of 11.6%. This is reasonable for most industries.
Qiagen N.V. (QGEN) generated $452.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More QGEN
Qiagen N.V. (QGEN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates